Characteristics of plexiform neurofibroma in patients suffering from Type-1 Neurofibromatosis. Pinar del Rio
Keywords:
Plexiform neurofibroma/diagnosis, genetics, complications, Neurofibromatoses/genetics, classification, diagnosis.Abstract
Plexiform neurofibroma is a complex tumor involving several tissues, this tumor provokes a massive distortion of the region where it is located leading to esthetical and medical problems. This work was aimed at knowing the frequency of plexiform neurofibromas in patients suffering from Type-1 neurofibromatosis, location, prevalence of sex and other clinical-genetic characteristics to design a protocol of diagnosis and treatment of plexiform neurofibromas in Pinar del Rio province. A descriptive, cross-sectional study was carried out in patients suffering from plexiform neurofibroma. Out of the total of patients, 34 presented plexiform neurofibroma, female sex prevailed. The majority of plexiform neurofibromas were located in limbs, torso and skull-face. The hyperpigmentation and the hypertrichosis were the most frequent clinical signs. A protocol was designed to accomplish the diagnosis and treatment of the patients affected.Downloads
References
1. Joseph H. Hersh, MD. Health Supervision for Children with Neurofibromatosis. Pediatrics [Internet]. Mar 2008 [citado 8 Jun 2012];121(3):[aprox. 12 p.]. Disponible en: http://neoreviews.aappublications.org/content/pediatrics/121/3/633.full.pdf+html
2. Ferner RE. Neurofibromatosis 1. Eur J Hum Genet [Internet]. 2007 [citado 8 Jun 2012]; 15(2):[aprox. 8 p.]. Disponible en: http://www.nature.com/ejhg/journal/v15/n2/pdf/5201676a.pdf
3. Casanova RT, González BC. Neurofibromatosis tipo 1. Medicentro 2008; 12(3): 1-5. http://www.medicentro.sld.cu/paginas%20de%20acceso/Sumario/ano%202008/v12n3a08.htm
4. Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromatosis Type 1 Revisited. Pediatrics [Internet]. Ene 2009 [citado 8 Jun 2012]; 123(1): [aprox. 12 p.]. Disponible en: http://pediatrics.aappublications.org/content/123/1/124.full.pdf+html
5. Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology [Internet]. Feb 2007 [citado 8 Jun 2012]; 68(9):[aprox. 5 p.]. Disponible en: http://www.neurology.org/content/68/9/643.short
6. Fisher MJ, Basu S, Dombi E, Yu JQ, Widemann BC, Pollock AN, et al. The role of [18F]-fluorodeoxyglucose positron emission tomography in predicting plexiform neurofibroma progression. J Neurooncol [Internet]. 2008 [citado 8 Jun 2012];87(2):[aprox. 7 p.]. Disponible en: http://dx.doi.org/10.1007/s11060-007-9501-5
7. Ferner RE, Golding JF, Smith M, Calonje E, Jan W, Sanjayanathan V, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol [Internet]. Feb 2008 [citado 8 Jun 2012];19(2):[aprox. 5 p.]. Disponible en: http://annonc.oxfordjournals.org/content/19/2/390.full.pdf+html
8. Jacquemin C, Bosley TM, Svedberg H. Orbit Deformities in Craniofacial Neurofibromatosis Type1. AJNR Am J Neuroradiol [Internet]. Sep 2003 [citado 8 Jun 2012];24(8):[aprox. 5 p.]. Disponible en: http://www.ajnr.org/content/24/8/1678.full.pdf+html
9. Lammert M, Friedman JM, Roth HJ, Friedrich RE, Kluwe L, Atkins D, et al. Vitamin D deficiency associated with number of neurofibromas in neurofibromatosis 1. J Med Genet [Internet]. Sep 2003 [citado 8 Jun 2012]; 43(10): [aprox. 5 p.]. Disponible en: http://jmg.highwire.org/content/43/10/810.full.pdf+html
10. Gachiani J, Kim D, Nelson A, Kline D. Surgical management of malignant peripheral nerve sheath tumors. Neurosurg Focus. Jun 2007; 22(6):13. PubMed PMID: 17613204.
11. Ferner RE. Neurofibromatosis 1. European Journal of Human Genetics [Internet]. 2007 [citado 8 Jun 2012]; 15(2):[aprox. 8 p.]. Disponible en: http://www.nature.com/ejhg/journal/v15/n2/pdf/5201676a.pdf

Published
How to Cite
Issue
Section
License
Authors who have publications with this journal agree to the following terms: Authors will retain their copyrights and grant the journal the right of first publication of their work, which will be publication of their work, which will be simultaneously subject to the Creative Commons Attribution License (CC-BY-NC 4.0) that allows third parties to share the work as long as its author and first publication in this journal are indicated.
Authors may adopt other non-exclusive license agreements for distribution of the published version of the work (e.g.: deposit it in an institutional telematic archive or publish it in a volume). Likewise, and according to the recommendations of the Medical Sciences Editorial (ECIMED), authors must declare in each article their contribution according to the CRediT taxonomy (contributor roles). This taxonomy includes 14 roles, which can be used to represent the tasks typically performed by contributors in scientific academic production. It should be consulted in monograph) whenever initial publication in this journal is indicated. Authors are allowed and encouraged to disseminate their work through the Internet (e.g., in institutional telematic archives or on their web page) before and during the submission process, which may produce interesting exchanges and increase citations of the published work. (See The effect of open access). https://casrai.org/credit/